Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Clinical trials involving over 10,000 participants showed no cancer signals compared to control groups
Weight Reduction Observations A 2025 network meta-analysis published in the Journal of the Endocrine Society compared data from separate clinical trials: A systematic review examining multiple agents reported: Tirzepatide (15 mg): Up to 17.8% weight reduction from baseline Retatrutide (12 mg): Up to 24.2% weight reduction from baseline Semaglutide (2.4 mg): Up to 14% weight reduction for reference Phase 2 Trial Results: Retatrutide Published in the New England Journal of Medicine, the Phase 2 trial of retatrutide in adults with obesity showed dose-dependent reductions in body weight of up to 24% after 48 weeks of treatment
Vasodilatory effect Studies showed that GIPR and GLP1R are present in the smooth muscle cells and endothelial arterioles and may have a cardioprotective effect due to endothelium-dependent vasodilation [105]
Think: a tiny bit of redness, slight swelling, or tenderness where the needle went in
Early studies in vascular patients concluded that heterozygosity for the mutations T833C and G919A of the CBS gene was associated with an abnormal response to a methionine load, which was caused by the heterozygosity (Boers, 1997b
